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Sleep and Orofacial Pain: 
Physiological Interactions and 
Clinical Management
Miguel Meira E Cruz, Bruno Sousa and Antoon De Laat
Abstract
Sleep and pain are both vital functions on which wellbeing, health, and life itself 
depend. These two complex states interact in several ways serving homeostasis, but 
they are also regulated by a well-orchestrated, multi-oscillatory mechanism char-
acterizing the Circadian Timing System. This interaction, which benefits critical 
physiological challenges, is also clinically crucial, as it mutually affects sleep and 
pain-related disturbances. It impacts pathophysiological pathways and relevant 
clinical aspects of many disorders. Furthermore, therapeutic success is frequently 
dependent on the adequate management of this cycle. The relationship of sleep and 
pain is undoubtedly of major relevance for diagnosis and successful management of 
various health conditions and disorders.
Keywords: sleep, orofacial pain
1. Introduction: basics of sleep-pain interaction
Sleep and pain interaction occur at several levels, both in physiology and 
pathology, and is influenced by a circadian timing system from which almost all 
functions in our body partially depend. Sleep and pain are both vital functions that 
ultimately contribute to general body homeostasis, and therefore to life success. 
Experience of pain motivates an individual to run away from potential physical 
injury and/or to stay protected and immobilized if an injury already occurred in 
order to promote and optimize recovery. While the escape-related response is tied 
to an increased state of arousal (being more awake), the response related to protec-
tion is linked to a state of rest (and sleep). Interestingly, sufficient sleep of good 
quality and pain have an inverse epidemiological relationship over the lifespan: 
sleep reduction, either in terms of duration or quality, increases from youth to old 
age, and at the same time pain-related complains follow a similar pattern. This rela-
tionship is clinically important since such negative interaction disturbs the internal 
milieu, and therefore impacts on prognosis of many disorders co-occurring  
with one or both of the symptoms of disturbed sleep and pain. Some of the most 
common pain-related conditions occur in the oro-maxillo-facial complex and are 
associated with emotional, psychological, and social disturbances that seriously 
compromise the patient’s quality of life. Thus, orofacial pain may by itself directly 
and indirectly interfere with sleep quality and sleep duration and consequently 
increases the severity of concomitant conditions and even the pain-related out-
comes. On the other hand, insufficient or inadequate sleep is known to contribute 
Sleep Medicine in Clinical Neurology
2
to an increased pain intensity and a reduction of pain tolerance. A vicious cycle 
can then be perpetuated, and therefore an adequate knowledge on the sleep-pain 
interaction-related mechanisms should be an important part of learning and train-
ing in the domain of clinical sleep neurology, which is in the scope of this book.
2. Pain classification: physiology and physiopathology of orofacial pain
Nociceptive impulses generated by potential or actual tissue damage are just one 
of the types of input that are continually assessed and evaluated throughout the 
various levels within the central nervous system (CNS). Nociception provides the 
brain a chance to interpret pains and make behavioral adjustments to avoid further 
potential damaging stimuli [1].
First-order nociceptive neurons, whether they synapse in the spinal trigeminal nucleus 
or in the dorsal horn, excite the same type of second-order neurons that respond 
to nociceptive signals as well as a variety of sensory stimuli and are therefore called 
wide-dynamic range neurons. These neurons conduct nociception and other sensations 
through the brainstem and display varying degrees of arborization with structures 
throughout the reticular formation, where baseline physiologic processes are controlled 
before reaching the third-order neurons in the thalamus [2–5]. Second-order neurons, 
stimulated by the faster conducting A-delta fibers, arborize less than those receiving 
impulses from the slower conducting C-fibers. While the A-delta fibers release gluta-
mate during this process, the C-fibers release a wide variety of neurotransmitters [6, 7]. 
The available information about the conduction velocity helps us to establish a connec-
tion between A-delta fibers and acute pain and between C-fibers and chronic pain.
Third-order circuits, which start in the thalamus and connect the sensory cortex 
with the basal ganglia and the limbic system, interpret nociceptive input [2, 8]. 
However, sometimes the pain source is difficult to locate even when pain is felt. For 
example, the cutaneous stimuli are easier to recognize than the stimuli from vis-
ceral organs and muscles just because dermis has much more free nerve endings. In 
response to pain interpretation, multilevel behavioral responses are coordinated, and 
descending motor commands are created. Whether nociception is delivered to the 
CNS through the spinothalamic tract or the trigeminal thalamic tract, pain perception 
evokes autonomic nervous system (ANS)-modulated cranial nerve responses [2, 9, 10].
Pain in the head and face often involves activation of the trigeminal ganglion 
nerves and the development of peripheral and central sensitization. The symptoms 
could be acute-like in toothache or chronic-like in migraine or temporomandibular 
disorders (TMD).
More important than a single nerve pathway, the expression “trigeminal system” 
alludes to a really complex course of action of, interneurons, nerve transmission 
fibers, and synaptic connection which process approaching information from 
the three divisions of the trigeminal nerve. This nerve is in fact a blended nerve 
containing both sensory and motor fibers. While sensory fibers innervate the face, 
conjunctiva, mucous membranes of the oral and nasal cavities, teeth, conjunctiva, 
dura mater of the brain, and intracranial and extracranial blood vessels, motor 
fibers support mostly the masseter, temporalis, and the other mastication muscles. 
Primary afferent neurons carry out sensory information from the face and mouth 
(except nociception) through trigeminal ganglion. The trigeminal-brain stem com-
plex is the place where a synapse with a second-order neuron occurs. This complex 
receives simultaneously afferent axons from the upper cervical (C2, C3), vagus, 
glossopharyngeal and nerves and afferent input primarily from the trigeminal 
nerve (facial pain and headaches may be a consequence of this connection between 
the upper cervical nerves and the trigeminal spinal tract nucleus).
3Sleep and Orofacial Pain: Physiological Interactions and Clinical Management
DOI: http://dx.doi.org/10.5772/intechopen.86770
We can separate the trigeminal-brain stem sensory nuclear complex in two differ-
ent structures: the trigeminal main sensory nucleus and the trigeminal spinal tract 
nucleus, also known as the nucleus of the descending tract of cranial nerve V [11]. 
The spinal tract nucleus is structured of three separate nuclei going from a rostral 
(superior) to caudal (inferior) direction: subnucleus oralis, subnucleus interpolaris, 
and subnucleus caudalis. Subnucleus caudalis is situated in the medulla, in some 
cases, stretching out to the dimension of C2 or C3 and it is the most important brain 
relay site of nociceptive information emerging from the orofacial area. Because the 
nucleus caudalis is anatomically continuous with, and structurally similar to, the 
spinal cord dorsal horn, and because it extends into the medulla as well, it is often 
referred to as the medullary dorsal horn [12]. Descending nerve fibers from higher 
levels of the CNS or medication can change or modulate incoming nociceptive 
signals to the subnucleus caudalis and projecting nociceptive signals on their way to 
the thalamus.
Inflammation and peripheral tissue injury increase the interaction between 
neuronal cell bodies and satellite glial cells within the trigeminal ganglion [13]. 
These interactions have been shown to play an important role in the induction 
and maintenance of peripheral sensitization of trigeminal nociceptive neurons. 
Under normal conditions, neuron-glia interactions in the trigeminal ganglia are 
involved in information processing, neuroprotection, and regulation of neuronal 
activity including the basal rate of spontaneous firing and threshold of activation 
to maintain homeostasis. While a transient increase in neuron-glia communication 
is associated with an acute response to inflammatory signals, stable gap junctions 
are formed between trigeminal neurons and satellite glia in response to sustained 
inflammation that is implicated in TMD’s [14].
Astrocytes, which are specialized glial cells, and the most abundantly found 
cells in the CNS, perform similar functions to satellite glia [15]. This means that 
they facilitate the regulation of neuronal development, synaptic coupling, repair, 
and even nutritional support. On the other hand, astrocytes can monitor and 
control the concentration of ions, neurotransmitters, and metabolites, as well as 
water movement, and thus play a key role in modulating the excitability state of 
neurons both in the brain and the spinal cord [16]. Microglia, other important 
glial cells present in the CNS, act as immune cells to remove cellular debris and 
dead cells; they also release inflammatory mediators to promote healing [17, 18]. 
Glial cells are responsible for regulating the extracellular environment around 
neurons and hence neuronal activities, and their importance in regard to the 
underlying pathology of many inflammatory diseases is gradually becoming 
recognized. Therefore, they have emerged as important cellular targets for thera-
peutic intervention given their role in promoting peripheral and central sensitiza-
tion and persistent pain [19].
3. Pathophysiological aspects of sleep-pain interaction
Understanding pathophysiological mechanisms of sleep-pain interaction 
requires first of all to be aware that some of those influences attributed to sleep 
could be in fact related to circadian modulation of both pain and sleep mechanisms.
3.1  Relationship between circadian timing system, sleep, and pain: a cyclic 
interaction
The circadian timing system is a complex neurophysiological network comprising 
a central biological clock, usually called the master pacemaker and several peripheral 
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oscillators, also known as peripheral clocks. The human master clock corresponds 
to a group of neurons located in the anterior part of the hypothalamus above the 
optic chiasm named the suprachiasmatic nucleus (SCN). Peripheral clocks are 
virtually present in all cells of the body. This time-related machinery dictates what 
we may consider an internal time which regulates almost all body functions in a 24-h 
periodic fashion. The Latin term “circadian” means circa-diem, about 1 day or 24 h, 
and this is because our clocks are adapted to the geophysical routine of the natural 
day-night cycle divided in the precise 24-h period of social time [20]. Both the period 
of human natural circadian rhythm and the sleep-wake cycle are not exactly 24 h but 
a little bit longer (more or less 24.6 h) consequently, a kind of hit on the clock should 
occur every day in order to get our body synchronized with social time. That is one 
of the main functions of melatonin, an hormone which is secreted in response to the 
absence of light and suppressed when light is present. The basic mechanism involves 
the activation or inhibition of photoreceptors in the eye’s retina which activate/
stop taking melanopsin to the suprachiasmatic nucleus stimulating or inhibiting 
melatonin secretion. Although mediated by these retinal ganglionic cell-related 
photoreceptors, the rods and cones also have photic inputs to SCN. Peripheral clocks 
within each cell have a mechanism which is identical to the clocks found in the SCN-
isolated neurons. However, although in isolation each cell is time-autonomous, they 
tend to generate a single circadian pattern dictated by SCN when these SCN neuronal 
population couple with other cells via humoral and non-humoral pathways [21, 22].
For biological clocks to be successful, they should accurately keep time and 
adjust to environmental signals. This requires adequate coupling between the SCN 
and peripheral clocks. In the absence of SCN signaling, peripheral clocks become 
desynchronized. As there is a tissue-specific time control that is in part locally 
controlled, loss of synchronization usually propagates and disturbs the circadian 
rhythm of such tissue as it was shown to occur in the liver [23–25] as well as in other 
tissues and organs within the human body.
3.2 The circadian regulation of pain
Some important features of pain are regulated by the circadian timing system. 
For instance, pain sensitivity follows a rhythmic cycle modulated by the 24 h 
biological clocks. However, it remains unclear whether rhythmicity is derived from 
daily oscillations within the underlying causes driving the pain or from rhythmic 
oscillatory component of the neural processing of pain. Pain-related rhythmic 
influences, however seem to be independent of either subjective or objective 
responses suggesting that its modulation occurs on a basic physiological level. 
Interestingly, this 24 h related pain modulatory mechanism is also dependent of 
pain intensity which in turn affects pain sensitivity in such a manner that the more 
intense the pain is, the greater the change in its sensitivity across the day. On the 
other hand, the particular type of pain seems relevant for the clinical impact of its 
circadian modulation. A recent prototype of human daily pain sensitivity curve was 
proposed (Figure 1).
3.3 Pain regulation by the homeostatic sleep drive
The sleep-wake cycle is the most conspicuous circadian rhythm in humans with 
a clear relationship with night (dark)-day (light) oscillation. Actually, sleep is itself 
regulated by a dual process comprising a circadian component and homeostatic one. 
This model presented by Borbely explains that we may predict a better sleep when it 
occurs at night and when we are tired compared to diurnal sleep and/or when we are 
full of energy.
5Sleep and Orofacial Pain: Physiological Interactions and Clinical Management
DOI: http://dx.doi.org/10.5772/intechopen.86770
The daily rhythm of pain sensitivity is affected not only by circadian rhythmic-
ity, but also by sleep-related homeostatic drive. Actually, either acute and chronic 
pain are correlated with sleep duration and sleep quality, but while results from 
distinct basic studies point to a specific modulation of sleep with a wide range of 
results, there is a lack of human experiments to consolidate clinical knowledge. For 
instance, even with standardized protocols, there are significant variations in the 
results [26] which make interpretation sometimes difficult.
3.4  Neural pathways for pain are regulated by both circadian and homeostatic 
components
The dorsal root ganglia have a circadian rhythmicity since clock genes—those 
genes generating a near 24 h rhythm—are expressed there. The role of circadian 
regulation of the neural circuitry underlying pain also involves the rhythmic 
expression of genes that facilitate synaptic transmission as calcium channel sub-
units and NMDA glutamate receptor subunits [27]. On the other hand, there are 
some studies showing that the majority of afferents in this route are nociceptors, 
thus suggesting that the circadian pattern is of nociceptive origin [27, 28].
Painful stimuli and non-noxious mechanical sensitivity are differently modu-
lated by the human circadian system since mechanical sensitivity peaks in the late 
afternoon (15–18 h); whereas, pain sensitivity peaks in the middle of the night 
(0–3 am). There is also a circadian component on inhibition of pain processing in 
the dorsal horn. It is however unclear what part of this inhibitory control is from the 
circadian machinery or dependent of the sleep homeostatic drive, since sleep depri-
vation is known to affect the higher levels of pain processing. Interestingly, phar-
macological agents that copy that top-down inhibitory control such as morphine are 
ineffective after severe sleep deprivation [29, 30] and there is evidence suggesting 
a neutral response of fast pain processing in case of sleep deprivation. On the other 
Figure 1. 
Prototypical human “daily pain sensitivity” curve (adapted from [31]), the graphic illustrates the circadian 
profile of pain sensitivity to different pain modalities (thermic: heat and cold, electrical, and nociceptive) and 
their variation during the 24 h of social day.
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hand, cortical responses to fast pain also seem to diminish after disturbed sleep. The 
relative balance of circadian versus homeostatic components in pain processing may 
depend on the specific type of pain [31].
Although there is still a lack of knowledge on the orofacial pain-sleep interac-
tion, basic and clinical evidence on both acute and chronic pain helps to elucidate 
the important role of these general components.
4. Orofacial pain diagnosis
The ability to understand and investigate the pathophysiologic processes under-
lying a disorder, depends on a valid, reliable classification system and common 
terminology to facilitate communication among clinicians, researchers, academi-
cians, and patients.
A review of the literature regarding the classification of orofacial pain reveals 
a lot of classification systems with varying advantages and disadvantages [20–43]. 
Despite all these classifications, currently, the most accepted among the clinicians 
and researchers dedicated to orofacial pain is the Research and Diagnostic Criteria 
for temporomandibular disorders (RDC/TMD and DC/TMD).
The taxonomy of “Diagnostic criteria for temporomandibular disorders” (DC/
TMD) is an evolution of the original “Research diagnostic criteria for temporo-
mandibular disorders” (RDC/TMD). It uses a dual-axis system in which, on Axis 
I, the physical diagnosis is based on pathophysiology and grading of chronic pain 
and on Axis II depression, anxiety, and non-specific physical systems are scored, 
in order to determine the distribution of subtypes of TMD, psychological disorders 
and psychosocial dysfunction [32, 33, 44, 45]. It is important to emphasize that 
with the advent of the RDC TMD, it was possible to describe and compare appro-
priate TMD subtypes and psychosocial profiles using clearly defined and validated 
diagnostic criteria in groups of TMD patients, and is used in different parts of the 
world [34, 35, 46, 47].
An accurate orofacial pain diagnosis is obviously the first step to achieve the 
correct treatment for the patient. This means that the clinician must be aware of 
both the Axis I and Axis II of the DC/TMD. The diagnostic process involves defin-
ing the inclusion criteria that are specific to a disorder as well as ruling out specific 
disorders that can cause similar symptoms.
Establishing the correct diagnosis in orofacial pain is particularly difficult 
because of the complex inter-relationship of physical and psychological factors in the 
etiology of biopsychosocial chronic pain syndromes. Thus, the differential diagnosis 
is a critical process that—if failed—can often lead to an inappropriate treatment.
The broad categories included in the new guidelines for Assessment, Diagnosis, 
and Management of Orofacial Pain are as follows [36, 48]:
• Vascular and nonvascular intracranial pain disorders
• Primary headache disorders
• Neuropathic pain disorders
• Intraoral pain disorders
• Temporomandibular disorders
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• Cervical pain disorders
• Extracranial and systemic causes of orofacial pain.
4.1 Vascular and nonvascular intracranial pain disorders
In this group, the differential diagnosis is essential since disorders like 
aneurysm, hemorrhage or hematoma, neoplasm, and edema can be life threat-
ening and may require immediate care. The signs and symptoms include new 
or abrupt onset of pain, severe pain, and interruption of sleep by pain. In 
addition, non-pain symptoms may occur. Weight loss, ataxia, weakness, fever, 
changes in the neurologic examination, and neurologic deficits are common  
[37, 38, 49, 50].
4.2 Primary headache disorders
Migraine and tension-type headache (TTH) are considered the most prevalent 
among primary headaches. TTH affects 60–80% of the population while migraine 
has a prevalence of 15% (male 7.6%, female 18.3%) [39, 51]. Cluster headache is not 
very common (0.1%) [40, 41, 52, 53]; however, it is often misdiagnosed and mis-
managed [42, 54]. Despite be a secondary headache disorder medication-overuse 
headache (MOH), it often co-exists with primary headache disorders, and conse-
quently they are described together.
4.3 Intraoral pain disorders
Dental and other oral diseases are very prevalent conditions in the general 
population. Pain complaints are the primary reason why most patients seek 
care from dental or medical doctors. Thus, regardless of intraoral pain is not 
exclusively a result of dental disorders, it is essential that all complaints of pain 
in the mouth and face are carefully studied in order to know if there is a dental 
problem in its origin. There are a lot of common somatic intraoral pain disorders, 
which can originate from disease involving one or more broad anatomic areas: 
the teeth, the surrounding soft tissues (mucosa and gingiva, tongue, salivary 
glands), and bone.
4.4 Neuropathic pain disorders
Neuropathic pain is defined as a symptom caused by a lesion or disease of 
the somatosensory system, including peripheral fibers (Aβ, Aδ, and C fibers) 
and central neurons. Its prevalence is about 7–10% among the general popula-
tion. Different causes of neuropathic pain have been described. Undoubtedly, 
there is a connection between neuropathic pain and population ageing as well 
as the increase of survival of cancer treatment and systemic diseases as diabetes 
mellitus. Indeed, imbalances between excitatory and inhibitory somatosensory 
signaling, alterations in ion channels, and variability in the way that pain mes-
sages are modulated in the central nervous system have been implicated in 
neuropathic pain. The challenge of chronic neuropathic pain is linked to the 
complexness of neuropathic symptoms, poor outcomes, and consequently dif-
ficult treatment options. The importance of the medication and other medical 
treatment is directly connected with the quality of life in patients suffering from 
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neuropathic pain. A multidisciplinary approach to the diagnosis and treatment 
of neuropathic pain is essential to achieve new and more efficient personalized 
intervention [43, 55].
4.5 Temporomandibular disorders
Temporomandibular disorder (TMD) is a general expression for pain, discom-
fort, and dysfunction of the masticatory muscles, the temporomandibular joints 
(TMJs), or both. TMD is the most common orofacial pain condition excluding 
dental pain. The main complaints from patients are regional pain in the face and 
periauricular area, limitations in jaw movement, and noise from the TMJs during 
jaw movements. Its prevalence is up to 15% in adults and 7% in adolescents. Long-
term pain is the most important reason why patients with TMD seek treatment. 
Psychological disabilities are often associated with TMD. As peripheral mecha-
nisms most likely play a role in the onset of TMD, a detailed muscle examination 
is recommended. The persistence of pain involves more central factors, such as 
sensitization of the supra spinal neurons and second-order neurons at the level 
of the spinal dorsal horn/trigeminal nucleus, imbalanced antinociceptive activ-
ity, and strong genetic predisposition, which also is included in DC/TMD. The 
etiology is multifactorial and still not clearly understood, but several biological 
and psychosocial risk factors for TMD have been identified. We have several 
treatment approaches to face temporomandibular disorders, including behavioral 
therapy, pharmacotherapy, physical therapy, and occlusal appliances. Evaluations 
indicated that the recently published Diagnostic Criteria for TMD (DC/TMD) are 
reliable and valid. These criteria cover the most common types of TMD and can be 
listed as follows.
4.5.1 Temporomandibular joint disorders
1. Joint pain
a. Arthralgia
b. Arthritis
2. Joint disorders
a. Disk-condyle complex disorders
i. Disk displacement with reduction
ii. Disk displacement with reduction with intermittent locking
iii. Disk displacement without reduction with limited opening
iv. Disk displacement without reduction without limited opening
b. Other hypomobility disorders
i. Adhesions/adherence
ii. Ankylosis
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1. Fibrous ankylosis
2. Osseous ankylosis
c. Hypermobility disorders
i. Subluxation
ii. Luxation
1. Closed dislocation
2. Recurrent dislocation
3. Ligamentous laxity
3. Joint diseases
a. Degenerative joint diseases
i. Osteoarthrosis
ii. Osteoarthritis
b. Condylolysis
c. Osteochondritis dissecans
d. Osteonecrosis
e. Systemic arthritis
f. Neoplasm
g. Synovial chondromatosis
4. Fractures
a. Closed fracture of condylar process
b. Closed fracture of subcondylar process
c. Open fracture of condylar process
d. Open fracture of subcondylar process
5. Congenital/developmental disorders
a. Aplasia
b. Hypoplasia
c. Hyperplasia
Sleep Medicine in Clinical Neurology
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4.5.2 Masticatory muscle disorders
1. Muscle pain limited to the orofacial region
a. Myalgia
i. Local myalgia
ii. Myofascial pain
iii. Myofascial pain with referral
b. Tendonitis
c. Myositis
i. Non-infective
ii. Infective
d. Spasm
2. Contracture
a. Muscle
b. Tendon
3. Hypertrophy
4. Neoplasms
a. Jaw
i. Malignant
ii. Benign
b. Soft tissues of head, face and neck
i. Malignant
ii. Benign
5. Movement disorders
a. Orofacial dyskinesia
i. Abnormal involuntary movements
ii. Ataxia
iii. Subacute
11
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b. Oromandibular dystonia
i. Acute
ii. Deformans
6. Masticatory muscle pain attributed to systemic/central disorders
a. Fibromyalgia
b. Centrally mediated myalgia
4.5.3 Masticatory muscle disorders
1. Headache attributed to TMD
4.5.4 Associated structures
1. Coronoid hyperplasia
4.6 Cervical pain disorders
Cervical pain disorders represent a very common group of musculoskeletal 
conditions that can greatly influence the head structures. We can divide it in two 
groups: those that primarily originate in the muscles and those that predominantly 
originate in the cervical spine. These structures very commonly refer pain to the 
orofacial region [44, 56].
4.7 Extracranial and systemic causes of orofacial pain
There are also some associated structures that can cause orofacial pain such 
as the eyes, ears, the nasal-paranasal sinus complex, the salivary glands, and the 
throat. In these cases, the orofacial pain is a heterotopic pain. At the same time, sys-
temic diseases like oromandibular dystonia, multiple sclerosis, and Lyme disease, 
often have orofacial manifestations. The importance of an accurate differential 
diagnosis is obviously tremendous.
5.  General considerations about clinical and epidemiological aspects of 
sleep-pain interaction
Clinical evidence on sleep-general pain interaction comes essentially from 
insomnia patients. The severity of the insomnia is associated with pain sensitivity. In 
a recent study, we showed that prevalence of insomnia in orofacial pain patients was 
almost 40%; in more than 600 clinical patients, approximately 1 in 6 suffered from 
relevant insomnia corroborating this important relationship between pain and sleep 
disturbance [57]. In a review on comorbidities of chronic facial pain and obstructive 
sleep apnea, Olmos also stated that sleep disturbances may impact orofacial pain in 
a bidirectional way [58]. Patients with obstructive sleep apnea (OSA) or with other 
respiratory problems during sleep, one of the most common causes of disturbed 
and insufficient sleep, may actually present with more pain-related complaints and 
we have recently showed that in a large sample of patients with temporomandibular 
disorders and chronic orofacial pain 22% of patients presented with snoring which 
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is the most common sign of sleep apnea. Furthermore, when snoring and insomnia 
complaints are considered together, 6% of those patients presented with both symp-
toms increasing the likelihood of suffering from OSA [59]. The reasons for the higher 
prevalence of pain in patients with sleep disturbances were discussed previously in 
the pathophysiological section and could be related with either peripheral  
(e.g., release of proinflammatory cytokines and decrease in pain tolerance) or 
central mechanisms. Often medication, commonly prescribed for pain management, 
affects breathing during sleep and can even interfere with other common sleep-
related disturbances. For instance, mechanical management for pain control may 
affect normal respiration predisposing to sleep related breathing disorders [60].
Sleep impairment and chronic pain are also independently related with 
increased depressive symptoms. It has been speculated that pain, sleep, and 
depression could share some neurobiological matrix. Anxiety, mood changes, and 
depressive symptoms are however a common feature in the sleep disturbed patient, 
chronic pain patient, and patient with comorbidly sleep-pain-related complaints. 
Therefore, in patients with these complaints, it is important to adequately address 
these three main aspects: Sleep, Pain, and Psychology.
6. Assessment of sleep-pain interaction
While diagnostic aspects and evaluation of pain were discussed along this chap-
ter and assessment of sleep was also detailed elsewhere in this book, it is important 
to consider some important diagnostic tools for an adequate assessment of the 
sleep-pain patient, such as self-reported questionnaires and polysomnography.
6.1 Self-reported measurements
An optimal use of self-report measures depends on the clinician’s degree of 
expertise and on the specific goal. There are several screening, diagnostic, and 
follow up tools which can be used to properly evaluate and manage patients with 
sleep-pain interaction conditions.
Sleep evaluation involves several dimensions and patterns which should be 
differently assessed according to the main complaint and prior clinical suspicion. 
A sleep diary is the gold standard for subjective sleep assessment and is always a 
simple good way to start understanding better the usual sleep pattern of the patient. 
There is a consensus sleep diary (CSD) [61] that resulted for the collaborative work 
of both insomnia experts and potential users. This instrument is unique regarding 
the important related methodological issues that allow to evaluate insomnia in the 
research field and practical arena.
Other self-reported instruments commonly used are the Pittsburgh sleep 
quality index [62], to evaluate sleep quality, the Epworth Sleepiness Scale [63] to 
evaluate sleepiness which could be intended as an indirect measure of inadequate 
sleep, the Sleep Questionnaire to characterize sleep depth, and dreams and a the 
Sleep Disturbance Questionnaire to assess mental anxiety and physical tension. 
The Global Sleep Assessment Questionnaire (GSAQ ) probably represents the best 
available screening tool for primary care practice. The chronotype as it could impact 
the sleep timing and the vulnerabilities for some pain sleep-wake cycle related 
impairments can be measured by the Morning-Evening Questionnaire [64], while 
states of sleepiness may be addressed by using the Stanford Sleepiness Scale [65] or 
the Karolinska Sleepiness Scale [66]. Visual analog scales oriented to sleep quality, 
sleepiness, or any other qualitative-measured dimension of sleep can also be used 
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and could provide important insights on the patient’s status. For screening of spe-
cific high prevalent sleep disorders like sleep apnea or insomnia, there are available 
simple validated questionnaires as the Berlin Questionnaire [67] or the Stop-Bang 
[68] for sleep apnea and the Insomnia Severity Index [69], for insomnia.
6.2 Objective assessment
Polysomnography is the gold standard for sleep evaluation if movement disor-
ders during sleep or parasomnias are suspected. In the case of disorders of central 
hypersomnolence, a Multiple Sleep Latency Test should be made after a PSG 
night in order to properly diagnose. Although PSG remains the gold option also to 
diagnose sleep disordered breathing, several simplified sleep studies are accepted 
and available. The American Academy of Sleep Medicine however recommends 
that PSG or home sleep apnea testing be used for diagnosis of uncomplicated adult 
patients presenting with signs and symptoms that indicate an increased risk of 
moderate to severe OSA. Important to note is that if a single home testing for sleep 
apnea is negative, inconclusive, or technically inadequate, PSG should always be 
performed for diagnosis in OSA. Furthermore, if a first PSG is negative and clinical 
suspicion for OSA remains, a second PSG should be considered [70].
7. Treatment of sleep-pain interaction
The orofacial pain diagnosis is clinical, but sleep studies may contribute to the 
objective establishment of orofacial pain interference with disturbed sleep.
The patient’s evaluation should include the identification of risk factors as 
higher levels of anxiety, alcohol consumption habits, use of long-term medication, 
sedentarism, stress, and a compromise in the quality of life. Patients commonly 
complain from non-restless sleep and higher levels of fatigue, headaches, sleepi-
ness, and anxiety.
Differential diagnosis could be difficult because of the occurrence of multiple 
sleep disturbances, which may mimic some aspects of pathological interaction 
between sleep and pain, either clinically or in a laboratory-based evaluation.
In patients with acute conditions, the efforts should be directed to the improve-
ment of nocturnal complaints in order to avoid chronicity. In chronic patients, 
symptom relief is associated to a better quality of life.
Whenever possible, identifying the primary disturbance allows an approach 
directed to the etiological factors and sleep hygiene as well as management of sleep 
disturbances should be objectives to pursue.
Pharmacological management not only should always attend to the possible 
interaction with pain- and sleep-related mechanisms, but also to the influences of 
circadian oscillations in the symptoms and in the treatment effect (chrono- 
pharmacological characteristics).
7.1 Nonpharmacological interventions
Although medications have been widely used for managing both pain and 
insomnia, such drugs are not free from adverse effects which many times may 
actually worsen one or both conditions or even be responsible for therapeutic 
withdrawal symptoms. Cognitive behavioral therapy is largely used for insomnia 
(CBT-I) and for pain (CBT-P) related conditions and is recognized as an effective 
first option approach to both conditions.
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7.2 Cognitive behavior therapy for insomnia (CBT-I)/disturbed sleep
Regarding sleep, cognitive behavior therapy for insomnia (CBT-I) proved to be 
superior to pharmacotherapy in several outcome studies [71, 72]. CBT-I consists 
of psychoeducation about sleep and insomnia, stimulus control, sleep restriction, 
sleep hygiene, relaxing training, and cognitive therapy.
Stimulus control techniques pretend to associate bed with a rapid sleep onset by 
teaching the patient to avoid habits other than sex and sleep in bed. Naps should 
also be avoided and regular sleep-wake schedules must be encouraged. Another 
important aspect is that the patient should learn only to go to bed when feeling 
sleepy and get out of bed if not asleep after 20 min [73].
Sleep restriction pretends to limit the amount of time spent in bed in relation to the 
actual time asleep. In the first days, this will lead to a mild sleep deprivation which 
soon will increase the sleep drive and afterwards to a more consolidated sleep with bet-
ter rest and efficiency. When the patient improves, time in bed will increase again [74].
Sleep hygiene contributes to more adequate behaviors near bedtime as avoiding 
caffeine or tobacco, intense exercise, or too much light, noise, and use of electronic 
devices [75].
Relaxation training will reduce cognitive and physical tension prior to bedtime. 
Techniques like hypnosis, meditation, and guided imagery can be used with more 
or less efficacy depending of personality and circumstances [76].
Cognitive therapy will help patient to have real beliefs regarding sleep and to 
adopt attitudes that will favor sleep. For instance, many patients lie in bed and think 
they will not sleep the whole night, making them worried about this. This technique 
also pretends to eliminate excessive rumination and negative thoughts, mainly in 
the bedtime [77].
Cognitive behavioral therapy is also available for other sleep disturbances such 
as sleep apnea, narcolepsy, sleep-wake circadian mismatch, and several pediatric 
disorders. Therefore, it could be used in several domains [78–80].
7.3 Cognitive behavioral therapy for pain (CBT-P)
Several psychological- and behavioral-related options showed to be effective 
for chronic pain, including CBT-P, acceptance and commitment, mindfulness, 
progressive muscle relaxation training, motivational interviewing, and goal set-
ting to behavioral activation. CBT-P is effective in a manner that its principles are 
associated to identify and approach those negative or dysfunctional thoughts and 
behaviors that usually worsen patient’s adjustment to chronic mechanisms of pain. 
It was shown to effectively reduce patient distress in patients with pain-associated 
conditions. Although it is expected that CBT-P also has impact on sleep in those 
patients, there are only few studies addressing this.
7.4 Combined cognitive behavioral therapy directed to both sleep and pain
A synergistic (CBT-I + CBT-P) approach was associated with significant greater 
improvements either in pain and sleep when compared with each isolated strategy. 
Fatigue, depression, and overall improvement in quality of live with less pain 
interference were observed in patients treated with this combination [81].
7.5 Pharmacological therapy
Reciprocal interaction between pain and sleep disturbance makes it important 
to concurrently address and treat both conditions in order to succeed. In some 
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patients, in which CBT is not successful or effective, pharmacological therapy is 
often required. Sometimes, also in the beginning of the therapeutic process, some 
classes of drugs are useful to optimize therapeutic adherence in both sleep and pain.
7.6 Opioids analgesics
Opioids may improve subjective sleep quality in some patients with chronic 
pain, but can also interfere with sleep in others, mainly if they have sleep related 
breathing disorders which may be aggravated by this class of analgesic drugs. Other 
well-known potential adverse effects are hyperalgesia, tolerance, and dependence. 
That is the reason to support the recommendation against the use of opioids for 
insomnia, although it could be effective in highly selected pain patients [82].
7.7 Benzodiazepine receptor agonists
This class of drugs binds to GABA (gamma aminobutyric acid)-A receptors and 
has sedative/hypnotic, amnestic, anxiolytic, muscle relaxant, and anticonvulsant 
effects. Many studies show that this GABA-mediated pharmacological activity 
favors sleep quality, reduces sleep latency, and wakefulness after sleep onset and 
improve total sleep time. Half-lives of BzRAS vary from short and intermediate 
to long, and therefore indications for sleep disturbance and insomnia depends 
of its clinical aspect (onset, maintenance, or end-stage insomnia) as well as their 
expected adverse effects (cognitive impairment, low attention levels, anterograde 
amnesia). Some controversies persist however regarding clinical improvements 
using these drugs on the long term. Long-term adverse reactions involve the 
increase in depressive symptoms, cognitive and psychomotor slowing. Its abrupt 
stop should not happen as rebound insomnia and seizures could appear or increase 
in intensity. Tolerance and dependence are also issues important to consider and in 
clinical practice it should be avoided to prescribe more than one benzodiazepine at 
the time since metabolites can combine and prolong sedation time. BzRAS should 
not be a first option in non-controlled patients with sleep disordered breath-
ing as they can disturb respiratory responses and therefore increase severity of 
sleep-related respiratory disturbances. Finally, it is crucial to appropriately taper 
the BzRA in order to prevent associated deleterious effects in comparison of their 
probable short time advantage [83].
7.8 Non-benzodiazepine benzodiazepine receptor agonists
The agents from this pharmacological class are active at the benzodiazepine 
GABA complex, particularly on receptors in the ventrolateral preoptic nucleus. 
Due to their proven efficacy, reduced side effects and less risk for addiction, 
non-benzodiazepine receptor agonists (non-BzRAs) became the most commonly 
prescribed hypnotic agents for onset and maintenance insomnia in the recent years 
[84]. Zolpidem, zaleplon, and eszopiclone belong to this newest class of FDA-
approved hypnotics. They improve sleep latency with fewer side effects given their 
shorter half-lives and receptor binding profile. While Zolpidem is currently the 
most prescribed drug for insomnia with no evidence of tolerance or rebound effect 
[85], Eszopiclone seems to have a similar safety profile but higher antidepressant 
and anxiolytic effects in patients with comorbid insomnia [86]. Regarding safety, 
behavioral effects of zolpidem, and zaleplon are much similar to triazolam and 
include sleep eating, sleep walking, and sleep driving. As recent data from zolpidem 
showed some negative cognitive impact on women, FDA recommended to lower the 
dose in females.
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7.9 Antidepressants
Antidepressants with sedative effect as tryciclic antidepressants (TCA), mir-
tazapine, and trazodone are often prescribed for insomnia comorbid with pain. 
Such pharmacological approach showed to relieve both insomnia, depressive, and 
pain-related symptoms. Often they are effectively used to treat neuropathic pain. 
Attention should be taken however regarding their differential effects on sleep. 
Imipramine and desipramine are less sedating and may disrupt sleep, amitriptyline, 
nortriptyline, trimipramine, and doxepine lead to a reduction in sleep latency, 
increase of sleep efficiency, and increase in sleep duration [87]. Those properties 
should be taken into account either on the prescription time or in the evaluation in 
order to control comorbid conditions.
Doxepin is approved as a hypnotic in doses from 1 to 6 mg and as an antidepres-
sant in doses from 150 to 300 mg. At hypnotic doses, it reduces wakefulness after 
sleep onset, increases sleep efficiency, and total sleep time without next day impact 
on diurnal excessive sleepiness [88].
The adverse effects of TCAs are mainly due to anti-adrenergic and anticholin-
ergic effects: orthostatic hypotension, xerostomia and xeropthalmia, constipation, 
and cardiac electric changes (delays in conduction). The risk of those side effects 
are age-related and particular care should be taken when prescribing TCAs to 
patients with comorbid depression and suicidal ideation because they are extremely 
lethal in overdose [89].
Trazodone, a type 2 serotoninergic, histaminergic and alfa1-adrenergic antago-
nist acts by inhibition of serotonin reuptake. As other antidepressants, trazodone 
has a hypnotic function at low doses whereas antidepressant effects occur at higher 
doses. It improves sleep in elderly, depressed, and anxious patients and patients 
with post-traumatic stress and has shown clear benefit in several painful condi-
tions. Side effects include sleepiness the next day, rebound insomnia, orthostatic 
hypotension, xerostomia, and priapism [90].
Mirtazapine, a sedative antidepressant agent, at doses of 15–30 mg, improves 
sleep onset, total sleep time, sleep efficiency, and wakefulness after sleep onset. 
Additionally, it has a positive impact on pain (recurrent headache and postherpetic 
neuralgia), mood, and appetite [91].
7.9.1  Selective serotonin (SSRI) and serotonin-norepinephrine reuptake  
inhibitors (SNRI)
This class of drugs is both effective for depression and pain, but it is linked to 
sleep disruption. So, whenever needed, attention should be paid to avoid its use in 
the evening hours [92].
7.10 Antipsychotics
Despite the limited evidence, some off-label atypical antipsychotics drugs 
(olanzapine, quetiapine, and risperidone) are used for managing sleep disruption 
and insomnia. Self-reported and objectively evaluated outcomes suggest efficacy in 
increasing sleep duration, slow wave sleep and decreasing sleep latency. However, 
long-term safety and efficacy studies should be done in order to corroborate these 
findings. Meanwhile, even in low dose (<150 mg/day) quetiapine was associated to 
xerostomia and dizziness. Some cases of hepatotoxicity, restless legs, and akathisia 
were also reported. Risperidone was associated to somnolence and sialorrhea and 
olanzapine is suggested to be related to a degree of sedation which impacts morning 
rising time [93].
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7.11 Anticonvulsants
GABA analogs Gabapentin and pregabalin are two anticonvulsants often used to 
treat chronic pain with comorbid insomnia and studies suggest positive effects on 
sleep outcomes as sleep latency and wakefulness after sleep onset as well as in deep 
slow wave sleep. Both are effective as adjuncts in depression and anxiety. Frequent 
adverse effects are dizziness, diurnal sedation, gastrointestinal problems, and 
peripheral edema [94].
7.12 Melatonin
Some studies show that melatonin, an hormone for regulating mammalian 
circadian biology exerts anti-nociception effects in animal models and humans, and a 
recent metanalysis strongly supports the utilization of melatonin on anti- 
nociception against many types of pain [95]; thus, suggesting that melatonin directed 
to comorbid condition should be effective without any major adverse effects.
7.13 Anti-histamines
The majority of over-the-counter agents used for sleep contain first generation 
anti-histamines with complementary anticholinergic effects. Those agents are asso-
ciated to a fast development of tolerance and the lack of long-term studies on these 
agents requires some caution particularly because of the link to diurnal sedation and 
impaired cognitive function [96].
7.14 Placebo effect
One relevant aspect not sufficiently discussed is the placebo effect, which can be 
sometimes one of the most important pieces of the treatment. Conceptualization of 
the placebo phenomenon has significantly changed during the last decades and this 
armamentarium is now intended as related to the patient’s perception of a treat-
ment. Of course, this is directly related to the patient’s previous experience and the 
patient-practitioner relationship and confidence as well as with expectations, emo-
tions, and beliefs. However, all those factors impact on cerebral function and release 
of endogenous opioids. Moreover, the placebo effect has a psycho-neurobiological 
base, since brain image studies performed in healthy volunteers show increased 
cortical activity particularly in the dorsolateral prefrontal cortex and orbitofrontal 
cortex, possibly associated with expectations of pain relief. On the other hand, 
the placebo analgesia is related to decrease of the neural activity in structures like 
thalamus, insula, and the anterior cingulate cortex, which constitute the so-called 
pain matrix [97]. The endogenous opioid system is probably involved in the placebo 
analgesia mechanism since opioid antagonists were shown to block the placebo 
effect [98]. Interestingly, the placebo mechanism was shown also to interfere with 
insomnia, even when patients did know they were taking a pharmacologically inac-
tive substance [99]. It is of crucial importance for clinicians to be aware of how the 
placebo components may affect (enhance or reduce) the outcome of active treat-
ment in chronic pain patients in order to separate either the therapeutic effect from 
the placebo one and to optimize treatment outcome.
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